192 related articles for article (PubMed ID: 31699399)
1. [Strategies in case of metastatic sentinel lymph node in breast cancer].
Costaz H; Rouffiac M; Boulle D; Arnould L; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Vincent L; Jankowski C; Coutant C
Bull Cancer; 2020 Jun; 107(6):672-685. PubMed ID: 31699399
[TBL] [Abstract][Full Text] [Related]
2. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
3. [Axillary management in breast cancer: The French practice versus recommendations in the post-2011 era].
Clavier A; Cornou C; Capmas P; Bats AS; Bensaid C; Nos C; Lécuru F; Ngô C
J Gynecol Obstet Biol Reprod (Paris); 2016 May; 45(5):451-8. PubMed ID: 26989008
[TBL] [Abstract][Full Text] [Related]
4. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
5. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
6. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
7. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
[TBL] [Abstract][Full Text] [Related]
8. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
[TBL] [Abstract][Full Text] [Related]
9. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
11. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
12. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
13. [Sentinel node and breast cancer: A state-of-the-art in 2019].
Zeitoun J; Babin G; Lebrun JF
Gynecol Obstet Fertil Senol; 2019 Jun; 47(6):522-526. PubMed ID: 30959186
[TBL] [Abstract][Full Text] [Related]
14. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
15. Practice Patterns of Radiation Field Design for Sentinel Lymph Node-Positive Early-Stage Breast Cancer.
Azghadi S; Daly M; Mayadev J
Clin Breast Cancer; 2016 Oct; 16(5):410-417.e3. PubMed ID: 27266803
[TBL] [Abstract][Full Text] [Related]
16. The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Ortega Expósito C; Falo C; Pernas S; Pérez Carton S; Gil Gil M; Ortega R; Pérez Montero H; Stradella A; Martinez E; Laplana M; Salinas S; Luzardo A; Soler T; Fernández Montoli ME; Azcarate J; Guma A; Petit A; Benitez A; Bajen M; Reyes Junca JG; Campos M; Ruiz R; Ponce J; Pla MJ; García Tejedor A
Breast Cancer Res Treat; 2021 Aug; 189(1):111-120. PubMed ID: 34089119
[TBL] [Abstract][Full Text] [Related]
17. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
18. Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.
Yuan Q; Hou J; He Y; Liao Y; Zheng L; Wu G
BMC Cancer; 2021 Mar; 21(1):293. PubMed ID: 33740930
[TBL] [Abstract][Full Text] [Related]
19. Axillary management still needed for patients with sentinel node micrometastases.
Cong BB; Yu JM; Wang YS
Cancer Manag Res; 2019; 11():2097-2100. PubMed ID: 30881133
[TBL] [Abstract][Full Text] [Related]
20. Comparing single or dual tracing modality on sentinel lymph node biopsy from patients who plan to omitting axillary lymph node dissection referring to the criteria of Z0011 trial: a retrospective study.
Xu Y; Wu H; Zhang W; Shen Y; Jiang Y; Meng L
Updates Surg; 2022 Jun; 74(3):1073-1078. PubMed ID: 35389176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
